Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.

Yasser GedRuby GuptaCihan DuzgolAndrea KnezevicNatalie ShapnikRitesh KotechaMartin H VossDarren R FeldmanOguz AkinSujata PatilRobert J MotzerBrian I RiniChung-Han Lee

Published in: BMC urology (2020)

Post IO-VEGF, most patients received VEGFR-TKIs. In this setting, VEGFR-TKIs demonstrated clinical activity and remain a viable option for salvage therapy after progression on IO-VEGF.

Keyphrases

vascular endothelial growth factor
endothelial cells
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
palliative care
prognostic factors
stem cells
patient reported outcomes
drug induced
smoking cessation
chemotherapy induced